PharmaCyte Biotech, Inc.
PharmaCyte Biotech, Inc. (PMCB): 3 pipeline candidates · ~78 mo cash runway. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
78.4 months
D/E 0.43 · 0% dilution
Lead: Preclinical
3 candidates
N/A
6 buys · 0 sells (180d)
A transparent, data-derived signal for PharmaCyte Biotech, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$8.7M
Cash
$20.2M
Quarterly Burn
$787K
Runway
78.4 mo
Revenue
$0
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| cypcaps | Preclinical |
| diabetes therapy | Preclinical |
| malignant ascites therapy | Preclinical |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
31
Total value held
$743K
| Holder | Shares | Value |
|---|---|---|
| citadel advisors llc | 519,747 | $346K |
| geode capital management, llc | 195,660 | $130K |
| vanguard capital management llc | 102,934 | $68K |
| renaissance technologies llc | 56,500 | $38K |
| xtx topco ltd | 52,362 | $35K |
| northern trust corp | 35,601 | $24K |
| schonfeld strategic advisors llc | 27,009 | $18K |
| vanguard fiduciary trust co | 23,452 | $16K |
| equitec proprietary markets, llc | 22,227 | $15K |
| simplex trading, llc | 19,940 | $13K |
Showing top 10 of 31 institutional holders of PharmaCyte Biotech, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in PharmaCyte Biotech, Inc.'s pipeline?
PharmaCyte Biotech, Inc. (PMCB) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is PharmaCyte Biotech, Inc.'s lead drug candidate?
PharmaCyte Biotech, Inc.'s most advanced tracked candidate is cypcaps (Preclinical) for Locally advanced, inoperable, non-metastatic pancreatic cancer (LAPC).
What is PharmaCyte Biotech, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, PharmaCyte Biotech, Inc. has approximately 78.4 months of cash runway.
What is PharmaCyte Biotech, Inc.'s market capitalization?
PharmaCyte Biotech, Inc.'s market capitalization is approximately $8.7M.
Who is the CEO of PharmaCyte Biotech, Inc.?
Mr. Joshua N. Silverman is the chief executive officer of PharmaCyte Biotech, Inc. (PMCB).
Get the full picture on PharmaCyte Biotech, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.